ponatinib is a potent inhibitor of the multidrug resistance-associated ATP-binding cassette transporter ABCG2
Interesting result, but it's going to be quite a while before we know if it will have any practical implications in the clinic. It does imply the possibility of substantial synergy with some chemo agents - likely most important in AML and secondarily in breast cancer expressing FGFR.
These studies will potentially be harder because it's plausible that because of this inhibition pona will change the PK/PD of the chemo it will be used with. So first they will have to sort out whether there is a drug/drug interaction, and if so, how the chemo dosage needs to be adjusted. Any combination with chemo can theoretically also be double-edged - for example in FLT3+ AML, pona would possibly protect the FLT3+ cells from chemo via cell cycle arrest.
Other TKI's (like Gleevec and Sutent) have similar properties (probably not as potent though).
As I've said before, the main cost of not partnering is that stuff like this is likely to progress much more slowly than if pona was in a full-scale broad development program by a big pharma.
Market Data 
Markets 
AI
